Rashmi Kanagal-Shamanna1. 1. Department of Hematopathology and Molecular Diagnostics, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, 77030, USA. RKanagal@mdanderson.org.
Abstract
PURPOSE OF REVIEW: Awareness, widespread availability, and routine use of sequencing techniques in work-up of myelodysplastic syndromes and acute myeloid leukemia have facilitated increased recognition of these entities arising in a background of germline predisposition disorders (GPD). RECENT FINDINGS: The latest revisions to the WHO classification of myeloid neoplasms incorporate "myeloid neoplasms with germline predisposition" as a separate entity due to the therapeutic implications of this diagnosis. It has become apparent that some of these entities have unique recognizable morphologic findings that can be challenging to interpret at time. Hence, much needs to be studied, posing a new layer of complexity to hematopathologists and oncologists. A thorough understanding of cytogenetic and molecular findings during disease evolution is essential. Consequently, hematopathologists and molecular pathologists play an increasing role in recognition of bone marrow morphologic features that help in recognition of underlying GPD, monitoring, and prompt identification of progression.
PURPOSE OF REVIEW: Awareness, widespread availability, and routine use of sequencing techniques in work-up of myelodysplastic syndromes and acute myeloid leukemia have facilitated increased recognition of these entities arising in a background of germline predisposition disorders (GPD). RECENT FINDINGS: The latest revisions to the WHO classification of myeloid neoplasms incorporate "myeloid neoplasms with germline predisposition" as a separate entity due to the therapeutic implications of this diagnosis. It has become apparent that some of these entities have unique recognizable morphologic findings that can be challenging to interpret at time. Hence, much needs to be studied, posing a new layer of complexity to hematopathologists and oncologists. A thorough understanding of cytogenetic and molecular findings during disease evolution is essential. Consequently, hematopathologists and molecular pathologists play an increasing role in recognition of bone marrow morphologic features that help in recognition of underlying GPD, monitoring, and prompt identification of progression.
Authors: Courtney D DiNardo; Mark J Routbort; Sarah A Bannon; Christopher B Benton; Koichi Takahashi; Steve M Kornblau; Rajyalakshmi Luthra; Rashmi Kanagal-Shamanna; L Jeffrey Medeiros; Guillermo Garcia-Manero; Hagop M Kantarjian; P Andrew Futreal; Funda Meric-Bernstam; Keyur P Patel Journal: Cancer Date: 2018-04-06 Impact factor: 6.860
Authors: Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman Journal: Blood Date: 2016-04-11 Impact factor: 22.113
Authors: Jane E Churpek; Khateriaa Pyrtel; Krishna-Latha Kanchi; Jin Shao; Daniel Koboldt; Christopher A Miller; Dong Shen; Robert Fulton; Michelle O'Laughlin; Catrina Fronick; Iskra Pusic; Geoffrey L Uy; Evan M Braunstein; Mark Levis; Julie Ross; Kevin Elliott; Sharon Heath; Allan Jiang; Peter Westervelt; John F DiPersio; Daniel C Link; Matthew J Walter; John Welch; Richard Wilson; Timothy J Ley; Lucy A Godley; Timothy A Graubert Journal: Blood Date: 2015-10-22 Impact factor: 22.113
Authors: Rashmi Kanagal-Shamanna; Sanam Loghavi; Courtney D DiNardo; L Jeffrey Medeiros; Guillermo Garcia-Manero; Elias Jabbour; Mark J Routbort; Rajyalakshmi Luthra; Carlos E Bueso-Ramos; Joseph D Khoury Journal: Haematologica Date: 2017-06-28 Impact factor: 9.941